Comparison of the outcomes of three detoxification methods (Clonidin, methadon, rapid) in opioid-dependents referred to kerman shaheed beheshti hospital in a 6 -month follow- up

Journal of Kerman University of Medical Sciences

Volumn 18, Issue 3, 2011, Pages 246-259

  Ziaadini, H ^a   Parvaresh, N ^a   Afshar, N ^a   Hoseinian, S M ^a   Sarhadi, R ^a   Hahdoost, A A ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Methadone; Naltrexone; Opiate substitution treatment; Relapse

Indexed keywords

CLONIDINE; METHADONE; NALTREXONE;

ABSTINENCE; ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFICACY; FOLLOW UP; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT SELECTION; PROSPECTIVE STUDY; RELAPSE;

EID: 79958819528     PISSN: 10239510     EISSN: 20082843     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Daly D.C, Alen Marlatt A.C. Relaps prevention. In: substance abuse a comprehensive textbook. Philadelphia, Williams & Wilkins, 2005; PP 773-775.
2. Colin ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia -assisted vs buprenorphine or clonidin assisted heroin detoxification and naltroxne induction. JAMA 2005; 294(8): 903-913.
3. Heydari Pahlavian A, Amirzargar M.A, Farhadinasab A, Mahjoob H. The comparison of personality trait among opioid dependents and non dependents of Hamedan city. Hamedan Univ Med Sci J 2003; 10(2): 55-63. [Persian].
4. Schufman E.N, porat S, Witztum E, Gandacu D, Bar- Hamburger R, Ginath Y. The efficacy of naltrexone in preventing re-abuse of heroin after detoxification. Biol psychiatry 1994; 35(12): 935-945.
5. Welsh Ch, Liberto J. The use of medication for relapse prevention in substance dependence disorders. Journal of Psychiatric Practice 2001; 7 (1): 15-31.
6. Kleber H. Treatment of narcotic addicts. Psychiat Med 1987; 3: 389-418.
7. O'Connor PG, Carrol K.M, Shi J.M, Schottenfeld R.S, Kosten T.R, Rounsaville B.J. Three Methods of opioid detoxification in a primary care setting. Annals of Internal Medicine 1997; 127(7): 526-530.
8. Rabinowitz J, Cohen H, Kotler M. Outcomes of ultrarapid opiate detoxification combined with Naltrexone maintenance and counseling. Psychiatr Serv 1998; 49(6):831-833.
9. Rabinowitz J, Cohen H, Atias S. Outcomes of Naltrexone Maintenance following ultra Rapid opiate detoxification versus Intensive Inpatient detoxification. Am J Addict 2002; 11(1): 52-56.
10. Brooner PK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE, et al. Psychiatric and substance use comorbidity among treatmentseeking opioid abusers. Arch Psychiatry 1997; 54: 71.
11. Nazer M.A, Khaleghi M.M, Syayxadi A.R. Prevalence of psychiatric disorders in opium dependents. Andishe & Raftar J 2002; 7(3): 38-45. [Persian]._
12. Jaffe J.H, Antony J.C. Substance related disorders. In:Sadock B. J, Sadock V. A. (editors), Kaplan& Sadock's Comprehensive textbook of psychiatry, 8th ed., Philadelphia, Lippincott Williams & Wilkins, 2005; PP 1274-1283.
13. Vazirian M, Mostashari G. Practical guide for treatment of substance abusers 2nd ed., The Ministry of Health and Medical Education, Tehran, 2002; PP 16-18. [Persian].
14. O'Connor P.G, Carroll KM, Shi J.M, et al. Three methods of opioid detoxification in a primary care setting. A randomized trial. Am Intern Med 1997; 127(7): 526-530.
15. Amato L, Davoli M, Ferri M, Ali R, Ferri M, et al. Methadone at tapered doses for the management of rapid withdrawal. Cochrane Database Syst Rev 2002; CD003409.
16. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multicenter randomized trial of buprenorphine- naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100(8): 1090-1100.
17. Sadock B. J, Sadock V. A. (eds). Kaplan & Sadock's Synopsis of psychiatry. 9th ed., Philadelphia, Lippincott Williams & Wilkins, 2007; p 449.
18. Rafieian M. Relaps among naltrexone users. Proceedings of the 3rd Congress of addiction, Yazd, Iran, 2004; 31. [Persian].